Course Description

The emergence of HER2-low therapies for metastatic breast cancer is a paradigm shift in the traditional binary classification of a patient’s HER2 status, creating a need for practice changes in pathology necessitated by the expansion in how HER2-low breast cancer needs to be classified and treated. During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel will discuss evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They will also discuss how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they will review some of the current challenges in HER2 testing and explore opportunities to prepare for the future landscape of HER classification in breast cancer. 

The activity offers 1.0 CME/CMLE credit. 

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. 

Faculty/Authors

Swikrity U. Baskota, MD
Assistant Professor, Department of Pathology, and Cell Biology
Columbia University Irving Medical Center 

Marilyn Bui, MD, PhD
Senior Member and Professor of Pathology
Scientific Director of Analytic Microscopy Core
Program Director of Cytopathology Fellowship
Moffitt Cancer Center & Research Institute 

Mamatha Chivukula, MD, FASCP
Director of Breast Pathology Services and IHC Lab
Mills Peninsula Medical Center, Sutter Health Affiliate 

Joseph Kim, MD, MBA, MPH
President
Q Synthesis 

Physician's Competency: Patient Care, Medical Knowledge.

CME/CMLE Credit: 1.0
Estimated Completion Time: 1.0 hour
Format: Online educational activity

Credit Designation Statement

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity. 

ASCP designates this enduring material for a maximum of 1.0 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel. 

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time 

Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online. 

Commercial Support 

Funded by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc. 

Provided by the American Society for Clinical Pathology in partnership with Q Synthesis. 

 
Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Click Go to Content and click the first module of the course.
3. Complete the Demographic Survey.
4. Review the Educational Activity.
5. Submit the course Evaluation.
6. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Upon completion of this activity, you will be able to:

• Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines 

• Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer 

• Update laboratory processes and procedures (eg, related to identification, tracking, and reporting) to prepare for the anticipated emergence of HER2-low as a diagnostic category of breast cancer 

• Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer 

• Apply principles of leadership to engage and inform members of the cancer care team about ongoing research around HER2-low breast cancer